ArticleFrontiers in endocrinology2025
A key role of the PGC-1α/ERR-α pathway in regulation of angiogenic factors in proliferative diabetic retinopathy.
Article in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Nuclear Receptor-Targeted Therapies: Reprogramming Metabolism with TRβ, ERRα, and LXR Modulators.Biomolecules · 2026Review
- Remodeling of the mitochondrial quality control network: natural products intervening in diabetic retinopathy.Frontiers in pharmacology · 2026Review
- Dysregulated hyaluronan metabolism drives inflammation and angiogenesis in proliferative diabetic retinopathy.Frontiers in immunology · 2026Article
- Potential Molecular Biomarkers for Predicting and Monitoring Complications in Type 2 Diabetes Mellitus.Molecules (Basel, Switzerland) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: PGC-1α is induced by hypoxia and interacts with the receptor ERR-α to stimulate angiogenic factors expression and promote angiogenesis. We investigated the possible role of the PGC-1α/ERR-α pathway in regulating angiogenic factors expression in proliferative diabetic retinopathy (PDR). Methods: We analysed vitreous fluid samples from PDR and non-diabetic patients and epiretinal fibrovascular membranes from PDR patients. Streptozotocin-treated rats were used as a model of diabetic retinopathy. Vitreous samples, epiretinal membranes, rat retinas, human retinal Müller glial cells and human retinal microvascular endothelial cells (HRMECs) were studied by Western blot analysis, ELISA and immunohistochemistry. Levels of reactive oxygen species (ROS) were determined with spectrofluorometric analysis. Results: Immunohistochemical analysis demonstrated co-expression of PGC-1α and ERR-α in endothelial cells and leukocytes in epiretinal membranes. Angiogenic activity, determined by the numbers of CD31-positive vessels, correlated significantly with PGC-1α and ERR-α expression levels. PGC-1α, ERR-α and the angiogenic biomarkers vascular endothelial growth (VEGF) and angiopoietin 2 were significantly increased in PDR vitreous samples. Diabetes induced upregulation of PGC-1α and ERR-α immunoreactive proteoforms in rat retinas. Cultured Müller cells and HRMECs constitutively expressed PGC-1α and ERR-α. In Müller cells, the PGC-1α inhibitor SR-18292 and the ERR-α selective inverse agonist XCT790 significantly attenuated VEGF, angiopoietin 2 and MCP-1/CCL2 upregulation induced by diabetic mimetic conditions. Treatment of Müller cells with the PGC-1α activator XLN005 induced significant upregulation of VEGF and attenuated ROS production induced by diabetic mimetic conditions. Conclusions: Our findings suggest that suppression of the PGC-1α/ERR-α pathway might impair the upregulation of angiogenic factors in PDR.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.